Tobam Trims Stock Position in Moderna, Inc. $MRNA

Posted by Geri Gentry on Jun 20th, 2026

Tobam trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 35.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 46,189 shares of the company’s stock after selling 25,609 shares during the period. Tobam’s holdings in Moderna were worth $1,362,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. AQR Capital Management LLC purchased a new position in shares of Moderna during the 1st quarter worth about $415,000. NewEdge Advisors LLC boosted its position in shares of Moderna by 732.7% in the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock worth $328,000 after acquiring an additional 10,185 shares during the last quarter. United Services Automobile Association purchased a new stake in Moderna in the first quarter valued at approximately $230,000. Focus Partners Wealth grew its holdings in Moderna by 58.7% in the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after purchasing an additional 8,706 shares during the period. Finally, American Century Companies Inc. increased its position in Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock worth $1,348,000 after purchasing an additional 2,410 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of MRNA stock opened at $63.96 on Friday. The company has a market capitalization of $25.38 billion, a PE ratio of -7.85 and a beta of 1.05. The firm has a fifty day simple moving average of $50.56 and a 200-day simple moving average of $45.23. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $67.74.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same period in the previous year, the business posted ($2.52) earnings per share. Moderna’s revenue for the quarter was up 260.2% on a year-over-year basis. Equities research analysts anticipate that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

Positive Sentiment: FDA advisers unanimously backed Moderna’s mRNA flu vaccine, boosting confidence that the shot could win approval and become a new revenue driver if the agency follows the panel’s recommendation. Article: MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
Positive Sentiment: Investor sentiment was also helped by reports that Moderna’s shares have been surging on the flu-vaccine catalyst, with some traders positioning for further upside ahead of the FDA’s final ruling. Article: US FDA advisers vote in favor of Moderna’s flu vaccine
Positive Sentiment: Unusually heavy call-option buying signals that some investors are betting the rally can continue as the FDA review progresses. Article: Moderna, Inc. (NASDAQ:MRNA) – Get Free Report
Neutral Sentiment: Moderna’s president sold shares under a pre-arranged trading plan, which is worth noting but does not necessarily indicate a change in the company’s outlook. Article: Moderna (NASDAQ:MRNA) President Sells $2,739,870.32 in Stock
Neutral Sentiment: The stock may stay volatile until the FDA makes its final decision on the flu vaccine by Aug. 5. Article: Moderna’s mRNA flu vaccine faces FDA advisory panel scrutiny

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the transaction, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. This trade represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 125,088 shares of company stock worth $6,193,713. Company insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the topic of several research reports. Barclays raised their price target on shares of Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. The Goldman Sachs Group increased their price objective on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Piper Sandler raised their target price on shares of Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a research note on Thursday. Finally, Royal Bank Of Canada lifted their target price on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a report on Monday, May 4th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $36.60.

Get Our Latest Report on MRNA

Moderna Profile

(Free Report)

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.